LabConnect, Inc. and Cryoport, Inc. have partnered to provide comprehensive logistics support for an upcoming Phase I/II clinical trial sponsored by Triumvira Immunologics Inc., a biopharma company developing a novel platform for engineering T cells to attack cancers. The study will investigate the safety and efficacy of autologous TAC-T Cells (TAC01-HER2) targeting HER2 in relapsed or refractory solid tumors.
 
The partnership will integrate Cryoport’s Cryoportal Logistics Management Platform and LabConnect’s SampleGISTICS platform to provide Triumvira with the highest possible available level of tracking and proactive management for their samples, source materials, and therapeutic product. Each step from scheduling, sample collection, confirming courier pickups/deliveries, and monitoring transport will be monitored by LabConnect and Cryoport project management.
 
LabConnect, a central lab for cell and gene therapy clinical trials, will utilize its virtual accessioning system and tracking platform SampleGISTICS to capture real time data from the time of sample and source material collection. LabConnect will also provide advanced analytical support, customized collection supplies, project management, and data management support.
 
Cryoport, a provider of temperature-controlled supply chain solutions for the life sciences, will provide its advanced logistics solutions designed for near real-time tracking and monitoring of clinical and commercial advanced therapy products. The temperature-controlled logistics solutions comprise Cryoport Express Shippers, which include its C3TM line of CRT (controlled room temperature) shippers, SmartPak II Condition Monitoring System and Cryoportal Logistics Management Platform.